Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
Metrics | Range | Conclusion |
---|---|---|
Selected LTM P/E Multiple | 35.7x - 39.5x | 37.6x |
Selected Fwd P/E Multiple | 16.5x - 18.3x | 17.4x |
Fair Value | ﷼36.82 - ﷼40.69 | ﷼38.75 |
Upside | -2.0% - 8.3% | 3.2% |
Benchmarks | - | Full Ticker |
Professional Medical Expertise Company | 957,400.0% | SASE:9574 |
Future Care Trading Co. | 954,400.0% | SASE:9544 |
Ayyan Investment Company | 214,000.0% | SASE:2140 |
National Medical Care Company | 400,500.0% | SASE:4005 |
Naba Al Saha Medical Services Company | 954,600.0% | SASE:9546 |
Scientific and Medical Equipment House Company | 401,400.0% | SASE:4014 |
- | - | - |
Select Price / LTM EPS Ratio | ||||||||
Benchmark Companies | ||||||||
9574 | 9544 | 2140 | 4005 | 9546 | 4014 | |||
SASE:9574 | SASE:9544 | SASE:2140 | SASE:4005 | SASE:9546 | SASE:4014 | |||
Historical Net Income Growth | ||||||||
5Y CAGR | NM- | NM- | NM- | 30.1% | NM- | -14.2% | ||
3Y CAGR | 10.3% | -35.5% | NM- | 29.8% | -5.5% | -24.9% | ||
Latest Twelve Months | 11.3% | -27.9% | -113.7% | 13.6% | -58.4% | -46.2% | ||
Historical Net Income Profit Margin | ||||||||
5 Year Average Margin | 10.9% | 29.1% | -32.2% | 18.0% | 21.9% | 6.2% | ||
Prior Fiscal Year | 9.9% | 26.8% | -13.2% | 22.3% | 28.7% | 6.3% | ||
Latest Fiscal Year | 8.8% | 18.4% | -34.3% | 23.0% | 11.2% | 3.7% | ||
Latest Twelve Months | 8.8% | 18.4% | -46.8% | 21.9% | 11.2% | 3.3% | ||
Current Trading Multiples | ||||||||
EV / LTM EBITDA | 8.1x | 109.9x | -19.3x | 20.9x | 22.5x | 19.6x | ||
Price / LTM Sales | 1.0x | 21.8x | 107.6x | 5.4x | 3.7x | 1.3x | ||
LTM P/E Ratio | 10.9x | 118.7x | -229.9x | 24.6x | 33.4x | 38.7x | ||
Low | Mid | High | ||||||
Benchmark LTM P/E Ratio | -229.9x | 24.6x | 118.7x | |||||
Historical LTM P/E Ratio | 20.3x | 35.8x | 184.3x | |||||
Selected P/E Multiple | 35.7x | 37.6x | 39.5x | |||||
(x) LTM Net Income | 29 | 29 | 29 | |||||
(=) Equity Value | 1,036 | 1,091 | 1,146 | |||||
(/) Shares Outstanding | 30.0 | 30.0 | 30.0 | |||||
Implied Value Range | 34.55 | 36.37 | 38.19 | |||||
FX Rate: SAR/SAR | 1.0 | 1.0 | 1.0 | Market Price | ||||
Implied Value Range (Trading Cur) | 34.55 | 36.37 | 38.19 | 37.56 | ||||
Upside / (Downside) | -8.0% | -3.2% | 1.7% |
Equity Value | |||||||
Benchmark Companies | |||||||
(in millions) | 9574 | 9544 | 2140 | 4005 | 9546 | 4014 | |
Value of Common Equity | 308 | 1,150 | 1,377 | 7,396 | 716 | 1,127 | |
(/) Shares Outstanding | 3.5 | 500.0 | 100.6 | 44.7 | 10.5 | 30.0 | |
Implied Stock Price | 88.00 | 2.30 | 13.68 | 165.50 | 68.15 | 37.56 | |
FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
Implied Stock Price (Trading Cur) | 88.00 | 2.30 | 13.68 | 165.50 | 68.15 | 37.56 | |
Trading Currency | SAR | SAR | SAR | SAR | SAR | SAR | |
FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |